Atherosclerosis
Volume 195, Issue 2 , Pages 269-276 , December 2007

Inhibition of plaque neovascularization and intimal hyperplasia by specific targeting vascular endothelial growth factor with bevacizumab-eluting stent: An experimental study

  • Christodoulos Stefanadis

      Affiliations

    • First Department of Cardiology, Hippokration Hospital, Athens Medical School, 9 Tepeleniou Str. 15452, Paleo Psychico, Athens, Greece
    • Corresponding Author InformationCorresponding author. Fax: +30 210 6457230.
    • ,
  • Konstantinos Toutouzas

      Affiliations

    • First Department of Cardiology, Hippokration Hospital, Athens Medical School, 9 Tepeleniou Str. 15452, Paleo Psychico, Athens, Greece
    • ,
  • Elli Stefanadi

      Affiliations

    • First Department of Cardiology, Hippokration Hospital, Athens Medical School, 9 Tepeleniou Str. 15452, Paleo Psychico, Athens, Greece
    • ,
  • Andreas Lazaris

      Affiliations

    • Department of Pathology, Athens Medical School, Athens, Greece
    • ,
  • Efstratios Patsouris

      Affiliations

    • Department of Pathology, Athens Medical School, Athens, Greece
    • ,
  • Nicholas Kipshidze

      Affiliations

    • Department of Interventional Cardiac and Vascular Services, Lenox Hill Hospital, New York, USA

Received 19 October 2006 ,Revised 18 December 2006 ,Accepted 21 December 2006.

References 

  1. Kumamoto M, Nakashima Y, Sueishi K. Intimal neovascularization in human coronary atherosclerosis. Hum Pathol. 1995;26:450–456
  2. Barger AC, Beeuwkes R, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N Engl J Med. 1984;310:175–177
  3. Wilson SH, Herrmann J, Lerman LO, et al. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation. 2002;105:415–418
  4. Moulton KS, Vakili K, Zurakowski D, et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA. 2003;100:4736–4741
  5. Stefanadis C, Vlachopoulos C, Karayannacos P, et al. Effect of vasa vasorum flow on structure and function of the aorta in experimental animals. Circulation. 1995;91:2669–2678
  6. Stefanadis CI, Karayannacos PE, Boudoulas HK, et al. Medial necrosis and acute alterations in aortic distensibility following removal of the vasa vasorum of canine ascending aorta. Cardiovasc Res. 1993;27:951–956
  7. Zhu XY, Rodriguez-Porcel M, Bentley MD, et al. Antioxidant intervention attenuates myocardial neovascularization in hypercholesterolemia. Circulation. 2004;109:2109–2115
  8. Ganaha F, Kao EY, Wong H, et al. Stent-based controlled release of intravascular angiostatin to limit plaque progression and in-stent restenosis. J Vasc Interv Radiol. 2004;15:601–608
  9. Rodriguez JA, Nespereira B, Perez-Ilzarbe M, Eguinoa E, Paramo JA. Vitamins C and E prevent endothelial VEGF and VEGFR-2 overexpression induced by porcine hypercholesterolemic LDL. Cardiovasc Res. 2005;65:665–673
  10. Kerwin W, Hooker A, Spilker M, et al. Quantitative magnetic resonance imaging analysis of neovasculature volume in carotid atherosclerotic plaque. Circulation. 2003;107:851–856
  11. O’Malley SM, Vavuranakis M, Naghavi M, Kakadiaris IA. Intravascular ultrasound-based imaging of vasa vasorum for the detection of vulnerable atherosclerotic plaque. Med Image Comput Comput Assist Interv Int Conf Med Image Comput Comput Assist Interv. 2005;8:343–351
  12. Bhardwaj S, Roy H, Heikura T, Yla-Herttuala S. VEGF-A, VEGF-D and VEGF-D(DeltaNDeltaC) induced intimal hyperplasia in carotid arteries. Eur J Clin Invest. 2005;35:669–676
  13. Celletti FL, Waugh JM, Amabile PG, et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 2001;7:425–429
  14. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  15. Yang J, Hawworth L, Sherry R. A randomised trial of bevacizumab, an antivascular endothelial growth antibody for metastatic renal cancer. N Engl J Med. 2003;349:427–434
  16. Abizaid A, Albertal M, Costa MA, et al. First human experience with the 17-beta-estradiol-eluting stent: the Estrogen And Stents To Eliminate Restenosis (EASTER) trial. J Am Coll Cardiol. 2004;43:1118–1121
  17. New G, Moses JW, Roubin GS, et al. Estrogen-eluting, phosphorylcholine-coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model. Catheter Cardiovasc Interv. 2002;57:266–271
  18. Kim W, Jeong MH, Cha KS, et al. Effect of anti-oxidant (carvedilol and probucol) loaded stents in a porcine coronary restenosis model. Circ J. 2005;69:101–106
  19. Farb A, Tang AL, Shroff S, Sweet W, Virmani R. Neointimal responses 3 months after (32)P beta-emitting stent placement. Int J Radiat Oncol Biol Phys. 2000;48:889–898
  20. Hehrlein C, Kaiser S, Riessen R, et al. External beam radiation after stent implantation increases neointimal hyperplasia by augmenting smooth muscle cell proliferation and extracellular matrix accumulation. J Am Coll Cardiol. 1999;34:561–566
  21. Daruwalla J, Nikfarjam M, Malcontenti-Wilson C, Muralidharan V, Christophi C. Effect of thalidomide on colorectal cancer liver metastases in CBA mice. J Surg Oncol. 2005;91:134–140
  22. Herrmann J, Lerman LO, Rodriguez-Porcel M, et al. Coronary vasa vasorum neovascularization precedes epicardial endothelial dysfunction in experimental hypercholesterolemia. Cardiovasc Res. 2001;51:762–766
  23. Moreno PR, Purushothaman KR, Sirol M, Levy AP, Fuster V. Neovascularization in human atherosclerosis. Circulation. 2006;113:2245–2252
  24. Fleiner M, Kummer M, Mirlacher M, et al. Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis. Circulation. 2004;110:2843–2850
  25. Moreno PR, Purushothaman KR, Fuster V, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation. 2004;110:2032–2038
  26. Stefanadis C, Toutouzas K, Stefanadi E, et al. First experimental application of bevacizumab-eluting PC coated stent for inhibition of vasa vasorum of atherosclerotic plaque: angiographic results in a rabbit atheromatic model. Hellenic J Cardiol. 2006;47:7–10
  27. Kipshidze NN, Iversen P, Kim HS, et al. Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. Catheter Cardiovasc Interv. 2004;61:518–527
  28. Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol. 2005;23:2574–2576
  29. Lewis AL, Willis SL, Small SA, et al. Drug loading and elution from a phosphorylcholine polymer-coated coronary stent does not affect long-term stability of the coating in vivo. Biomed Mater Eng. 2004;14:355–370
  30. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
  31. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–231
  32. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–65
  33. Midgley R, Kerr D. Bevacizumab-current status and future directions. Ann Oncol. 2005;16:999–1004

PII: S0021-9150(07)00033-0

doi: 10.1016/j.atherosclerosis.2006.12.034

Atherosclerosis
Volume 195, Issue 2 , Pages 269-276 , December 2007

Article Tools

* Image Usage & Resolution